Table 3.
Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) measures1 of statin users2 prior to and following breast cancer diagnosis and treatment by adherence status
| All statin users | LDL (mg/dL) | High LDL4 ≥130mg/dL | HDL (mg/dL) | Low HDL4 <50mg/dL | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Observation period | N | Mean | SD | IQR | n | (%) | Mean | SD | IQR | n | (%) | |||||
| Diagnosis − 1 year | Year −1 | 938 | 143.3 | (35.2) | 116– 163 | 564 | 60.1 % | 50.7 | (10.6) | 43–59 | 426 | 45.4 % | ||||
| Diagnosis + last treatment | Treatment period5 | 701 | 150.3 | (35.6) | 122–172 | 496 | 70.8 % | 51.26 | (10.4) | 44–59 | 338 | 48.2 % | ||||
| Last treatment + 1 year | Year +1 | 884 | 143.46 | (36.7) | 114–157 | 519 | 58.7 % | 51.16 | (11.0) | 43–60 | 416 | 47.1 % | ||||
| End of year 1 +1 year | Year +2 | 670 | 139.5 | (35.5) | 114–153 | 356 | 53.1 % | 50.86 | (10.6) | 43–59 | 330 | 49.3 % | ||||
| End of year 2 +1 year | Year +3 | 625 | 141.26 | (37.1) | 110–159 | 321 | 51.4 % | 50.56 | (11.3) | 42–63 | 297 | 47.5 % | ||||
| MPR3 ≥ 0.8 | LDL (mg/dL) | High LDL4 ≥130mg/dL | HDL (mg/dL) | Low HDL4 <50mg/dL | ||||||||||||
| Observation period | N | Mean | SD | IQR | n | (%) | Mean | SD | IQR | n | (%) | |||||
| Diagnosis − 1 year | Year −1 | 326 | 123.1 | (37.6) | 95–144 | 118 | 36.3 % | 53.6 | (9.7) | 47–61 | 111 | 34.0 % | ||||
| Diagnosis + last treatment | Treatment period5 | 238 | 120.76 | (42.4) | 92–135 | 71 | 29.8 % | 53.96 | (9.0) | 47–61 | 74 | 31.1 % | ||||
| Last treatment + 1 year | Year +1 | 278 | 116.3 | (36.1) | 90–130 | 78 | 28.1% | 52.76 | (10.7) | 45–61 | 104 | 37.4 % | ||||
| End of year 1 +1 year | Year +2 | 169 | 112.9 | (37.0) | 86–127 | 42 | 24.9% | 53.76 | (11.1) | 46–64 | 68 | 40.2 % | ||||
| End of year 2 +1 year | Year +3 | 210 | 114.2 | (35.9) | 95–137 | 50 | 23.8 % | 50.6 | (11.6) | 41–62 | 78 | 37.1 % | ||||
| MPR3 < 0.8 | LDL (mg/dL) | High LDL4 ≥130mg/dL | HDL (mg/dL) | Low HDL4 <50mg/dL | ||||||||||||
| Observation period | N | Mean | SD | IQR | n | (%) | Mean | SD | IQR | n | (%) | |||||
| Diagnosis − 1 year | Year −1 | 622 | 143.7 | (40.8) | 112–169 | 446 | 71.7 % | 50.8 | (10.5) | 44–59 | 315 | 50.6 % | ||||
| Diagnosis + last treatment | Treatment period5 | 463 | 160.4 | (40.0) | 131–185 | 425 | 91.8 % | 49.96 | (10.5) | 42–58 | 264 | 57.0 % | ||||
| Last treatment + 1 year | Year +1 | 606 | 137.6 | (39.0) | 119–161 | 441 | 72.7 % | 50.16 | (10.5) | 42–58 | 299 | 49.3 % | ||||
| End of year 1 +1 year | Year +2 | 501 | 134.4 | (39.1) | 105–154 | 314 | 62.7 % | 49.66 | (10.7) | 42–58 | 252 | 50.3 % | ||||
| End of year 2 +1 year | Year +3 | 415 | 133.0 | (39.7) | 117–159 | 247 | 59.5% | 51.86 | (11.8) | 44–60 | 214 | 51.6 % | ||||
Fasting lipid profile measures, highest of LDL and lowest of HDL in the observation period
≥1 Dispensing of statin medication in the year prior to breast cancer diagnosis
Medication possession ratio (MPR): proportion of days’ supply medication dispensed over the observed days of intended use; patients considered adherent at MPR ≥ 0.8, non-adherent at MPR < 0.8
Third report of the National Cholesterol Education Program (NCEP) Expert Panel, Adult Treatment Panel III – Approach to treatment, goals and thresholds: LDL <130 mg/dL and HDL ≥50 mg/dL; Circulation 2002; 106(25): 3143-421.
Treatment period: SEER diagnosis date to the latest of primary cancer treatment (surgery, radiation, or chemotherapy) plus 90 days
Not statistically different (P > 0.05) in comparison to Year-1
Abbreviations: SD Standard deviation; IQR Interquartile range; LDL Low-density lipoprotein; HDL High-density lipoprotein